KPMG has been appointed administrators to Phion Therapeutics Limited, a Queen’s University spin-out that has raised over €25 million in equity since it was founded. Accountants James Neill and John Donaldson were appointed administrators to the Belfast-headquartered biotechnology company, which develops ground-breaking nucleic acid vaccines and therapeutics. Phion Therapeutics has raised funds from various private investors and Innovate UK. Its largest investor is invoX Pharma, an integrated biopharmaceutical company. InvoX Pharma was founded in March 2021 by Sion Biopharma, a Hong Kong-listed global top-40 pharmaceutical company. Phion Therapeutics’ lead product is a therapeutic vaccine against cancers driven by HPV (a…

Want to continue reading?

Introductory offer: Sign up today and pay €200 for an annual membership, a saving of €100.

Subscribe

Cancel anytime.

Are you already a member? .